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Abstract
Background: At present, seroreactivity is not a valuable parameter for diagnosis of Human
Papillomavirus (HPV) infection but, it is potentially valuable as marker of viral exposure in
elucidating the natural history of this infection. More data are needed to asses the clinical relevance
of serological response to HPV.
Objectives: The objective was to assess the clinical and epidemiological correlates of HPV-
seroreactivity in a cohort of HIV-negative and HIV-positive women.
Methods: Seroreactivity of 96 women, evaluated in an ELISA test based on denatured HPV16 late
(L) and early (E) antigens, was correlated with their clinical and epidemiological data previously
collected for a multi-centre Italian study, HPV-PathogenISS study.
Results: No significant correlation was found between HPV DNA detection and seroreactivity.
Women, current smokers showed significantly less seroreactivity to L antigens as compared with
the non-smokers. HIV-positive women showed significantly less (66.7%) antibody response as
compared with HIV-negative women (89.3%), with particularly impaired response to L antigens.
Women, HIV-positive and current smokers, showed by far the lowest seroprevalence (33.3%) as
compared to 75.9% among all other women (OR = 0.158; 95%CI 0.036–0.695, p = 0.014; Fisher's
exact test). Importantly, this association did not loose its significance when controlled for
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confounding from age (continuous variable) in multivariate analysis or using Mantel-Haenszel test
for age-groups.
Conclusion: It is tempting to speculate that HIV-positive current smokers comprise a special high-
risk group, with highly impaired immunological response that could prevent eradication of
persistent HPV infections and thus contribute to development of CIN3/CC.
Background
Human Papillomavirus (HPV) infection, known to be
associated with both benign and malignant tumours at
different mucosal sites, is widespread among female and
male populations [1,2]. The oncogenic high-risk HPV
types (HR-HPVs) are the single most important etiological
agents of cervical cancer (CC) and its precursor (CIN)
lesions [3,4]. Despite global differences in the prevalence
of individual HR-HPV types, HPV16 remains the most fre-
quent HR-HPV type in all geographic regions and the cur-
rent HPV research is mostly focused on it [3,4]. Diagnosis
of HPV infection is based on detection of viral DNA using
different PCR-based methods or commercially available
hybrid capture (HC2) test [5,6]. Until now, serological
studies have had little to offer in diagnosis of HPV infec-
tions [7]. The first serological assays for HPV antibody
detection were introduced in the early 1970's [8], but the
more widespread use of HPV serology had to await the
development of more refined assays based on virus-like
particles (VLP) in the early 1990's [9,10]. A growing body
of serology data has being obtained using different viral
protein-based ELISA to analyse HPV antibodies in differ-
ent settings, most notably in large-scale seroepidemilogi-
cal- and case-control studies to assess the risk factors of
cervical carcinoma (CC) in HPV exposed subjects [11-17].
The main conclusion from the plethora of sero-epidemio-
logical studies is that antibody response to viral proteins
does not invariably occur during a natural HPV infection
[14,15]; only half of HPV DNA-positive women with nor-
mal cytology shows antibody response to VLPs [18,19].
HPV E6/E7 antibodies are predominantly found in
patients with CC, but they are also detected in healthy
controls, precluding the use of their detection as predictor
of CC [14,15,20].
VLP-based assays have been recognized as reliable geno-
type-specific assays [14,15,21] and potentially will con-
tribute to the understanding of the natural history of HPV
infections [18,19,22]. New L1VLP-based vaccines have
been shown to induce levels of HPV type specific antibod-
ies higher than that found in natural infected women
[23]. Correlation between anti-L1VLPs antibodies and
protection from reinfection in natural infection is still a
controversial issue [24,25]. An important problem with
serological studies resides in the fact that the results from
different laboratories are not comparable for the lack of
reference specific sera [26]. For the serological response
evaluation of the new HPV vaccines the WHO recom-
mends the standardisation of the different in-house L1-
based serological methods by the use of reference sera and
promoted an international collaborative study with this
proposal [21].
To improve the understanding of correlation between
infection and antibody response in patients with and
without cervical lesions, prospective cohort studies using
a widespread panel of viral antigens would be needed
[14,15,26]. Similarly, it would be necessary to study the
dynamics of HPV-E and -L antigen-specific antibodies in
relation to their clinical and epidemiological correlates
[27,28], including immune-suppression due to HIV infec-
tion [25,29]. There are recent growing evidences regarding
the induction of antibodies neutralising across papilloma-
virus types after vaccination with VLP displaying L2
epitopes or with fusion protein containing L2E7E6 viral
proteins or synthetic peptides of the HPV16 L2 protein
[30-32]. Very recently Rizk and collaborators [33] have
shown that L1 fused to GST protein displays a broad vari-
ety of epitopes, both conformational and linear; the neu-
tralising ones are conformational and, mostly, type
specific while the cross-reacting ones are associated with
linear epitopes.
We have recently reported the development of an in-
house ELISA test based on five recombinant HPV16 pro-
teins expressed in E. coli: L1 and L2 capsid proteins, E6
and E7 oncoproteins and the non-structural E4 protein,
all used in unfolded form [34]. The idea of using dena-
tured antigens comes from the observation of a high
amino acid identity, ranging from 36% for E6 to 74% for
L1, among the same proteins belonging to different HPV
genotypes and then the possibility to detect cross-reacting
antibodies directed against linear epitopes. By this assay
we were able to detect an antibody response in women
infected with HPV genotypes different from that of the ref-
erence antigen. In this study we also determined the Avid-
ity Index (AI) [35] of the positive samples. Antibody
response to linear epitopes has been reported in the past
[36,37] and was correlated to the specific stage of HPV-
associated cervical disease [38]; nevertheless this antibody
response can not be related to protection level against
HPV infection, that is associated to the neutralising com-
ponent of humoral response. Our system, revealing anti-
bodies only against linear epitopes, could be utilized toInfectious Agents and Cancer 2008, 3:9 http://www.infectagentscancer.com/content/3/1/9
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evaluate the immunological responsiveness of subjects to
HPV infection and contribute to estimate the risk of infec-
tion progression but it could not provide information
about protection level from reinfection in both natural
infection and after vaccination.
In the present study we have correlated the antibody
response, evaluated with our system, to the baseline epi-
demiological, clinical and HPV DNA data of women
enrolled in a multi-centre cohort study designed to
explore pathogenetic mechanisms and prognostic factors
of CIN lesions in HIV-positive and HIV-negative women,
known as HPV-PathogenISS study [39].
Results
Correlation of epidemiological characteristics to 
serological response
The recorded epidemiological characteristics of the
enrolled women have been correlated to their serological
response to either all HPV16 antigens, or separately E and
L proteins (Table 1). The statistical analysis shows that
antibody response is not related to patient's age or their
ethnic origin (data not shown); however, the power of the
study to detect true differences in the age between the two
groups is limited, due to the small sample size. Interest-
ingly, current smokers have significantly (p = 0.009) less
seroreactivity to L antigens as compared with the non-
Table 1: Key epidemiological data of patients related to their serological response to HPV16 antigens
Variables Anti-E and -L Anti-E4-E6 and E7 Anti L1 and -L2
+ - Sign. + - Sign. + - Sign.
Mean Age (yrs) 34.9 36.9 p = 0.460 34.8 36.0 p = 0.533 36.1 35.6 p = 0.805
Smoking status %
Non-smoker (40) 92.5 7.5 OR = 2.8 (0.7–11.3);  72.5 17.5 OR = 1.4 (0.6–3.6);  85.0 15.0 OR = 3.7 (1.3–10.5); 
p = 0.211 p = 0.495 p = 0.009
Current smoker (48) 81.3 18.7 64.6 35.4 60.4 39.6
N. cigarette/d 13.4 10.1 p = 0.285 13.8 10.9 p = 0.225 13.3 12.0 p = 0.603
Age start smoking (yrs) 18.9 19.6 p = 0.776 18.2 20.6 p = 0.122 19.5 18.1 p = 0.379
Years smoked 15.2 13.3 p = 0.592 16.5 12.0 p = 0.089 14.0 16.8 p = 0.296
1Contraception (%):
Yes (53) 92.5 7.5 OR = 1.4 (0.3–6.8);  73.6 26.4 OR = 1.3 (0.5–3.4):  73.6 26.4 OR = 0.7 (0.2–2.1): 
p = 0.694 p = 0.658 p = 0.560
No (29) 89.7 10.3 69.0 31.0 79.3 20.7
^New partner (%):
Yes (5) 100 - OR = NC; p = 0.508 60.0 40.0 OR = 0.7 (0.2–2.2);  60.0 40.0 OR = 0.7 (0.2–2.1); 
p = 0.630 p = 0.619
No (76) 86.8 13.2 71.1 28.9 72.4 27.6
Sexually active (%):
Yes (79) 89.9 10.1 OR = 5.9 (0.9–40.9);  70.9 29.1 OR = 1.6 (0.3–10.4);  74.7 25.3 OR = 4.4 (0.7–28.4); 
p = 0.105 p = 0.631 p = 0.124
No (5) 60.0 40.0 60.0 40.0 40.0 60.0
Partner HIV+ (%):
Yes (8) 87.5 12.5 OR = 0.9 (0.1–8.7); 87.5 12.5 OR = 3.3 (0.4–28.3); 62.5 37.5 OR = 0.6 (0.1–2.8); 
p = 1.000 p = 0.679
No (75) 88.0 12.0 68.0 32.0 73.3 26.7
2Actual contraception %
Yes (37) 86.5 13.5 OR = 0.7 (0.2–2.7);  67.6 32.4 OR = 0.8 (0.3–2.1);  64.9 35.1 OR = 0.4 (0.1–1.1); 
p = 0.726 p = 0.660 p = 0.093
No (43) 90.7 9.3 72.1 27.9 81.4 18.6
2Condom Use %
Never (43) 90.7 9.3 72.1 27.9 72.1 27.9
Often (14) 100 - p = 0.138 78.6 21.4 p = 0.334 100 - p = 0.022
Always (18) 77.8 22.2 55.6 44.4 61.1 38.9
STD since last visit %
Yes (6) 100 - OR = NC;  100 - OR = NC;  83.3 16.7 OR = 1.7 (0.2–15.7)
p = 1.000 p = 0.175
No (74) 89.2 10.8 68.9 31.1 74.3 25.7
NC, non-computable; 1Contraception used until past; 2Contraception in current use; *For linear trend; HPV-NCIN, HPV infection without CIN.... 
^New partner since last visitInfectious Agents and Cancer 2008, 3:9 http://www.infectagentscancer.com/content/3/1/9
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smokers (OR = 0.26; 95%CI 0.095–0.764), whereas the
difference in reactivity to E and E+L antigens is not signif-
icant. No differences in seroreactivity could be attributed
to the other smoking variables (age at onset, number of
cigarettes/day, smoking years) (data not shown), or to any
of the indicators of obstetric history or sexual behaviour,
including contraception used in the past. Women's sero-
reactivity was not influenced by their being sexually
active, their having a new partner since the last visit in the
clinic, or their having a HIV-positive sex partner. Interest-
ingly, the actual mode of contraception itself was not sig-
nificant, but the different practice of condom use was
significantly (p = 0.022) related to seroreactivity to L anti-
gens, being the least frequent among women using always
condom in sexual intercourse.
Correlation of clinical data to serological response
The key clinical data were then related to HPV seroreactiv-
ity; the results are shown in Table 2. Seroreactivity to E, L
or E & L antigens seems to be not associated with HPV
DNA positivity, either for all HPVs or for LR-HPV and HR-
HPV genotypes separately. Other baseline clinical data, as
the reported past HPV infection, abnormality in the refer-
ral Pap smear and grade of CIN, were analysed regarding
the sero-status. Only a reported past HPV infection was
associated with significantly (p = 0.046) higher probabil-
ity of having antibodies to E antigens (OR = 4.8; 95%CI
1.1–22.8). No statistical correlation was found between
the sero-status and the other considered clinical data, as
the presence of external genital warts (Condylomata acu-
minata) or their number (data not shown). Mild abnor-
mality on colposcopy was found associated with
significantly increased seropositivity to L antigens, as
compared with normal or high-grade colposcopy (p =
0.015), no such difference was found in reactivity to E or
to E+ L antigens.
The key epidemiological and clinical data were also
related to the AI values of L and E antigens determined in
a previous study [34]. This is a useful parameter used in a
large number of viral diseases to discriminate between
low and high antibody avidity; 40% is considered the dis-
crimination AI value [40-42]. In our system AI has been
considered as an indirect measure of the specific interac-
tion between antigen and cross-reacting antibodies. Most
reactions with L1, L2, E4 and E7 antigens showed an AI
higher than 40%, but not those reacting with E6 antigen.
Few significant associations were observed between high
AI and the different epidemiological and clinical varia-
bles. High AI of E7 antibodies was associated with 100%
of women who did not use contraception in the past, as
compared with 80% among women who used regular
contraception (p = 0.044). Similarly, regular use of con-
dom was marginally (p = 0.076) associated with lower
probability of high-avidity antibodies to L1. None of HR-
HPV negative women had high-avidity antibodies to E6,
as compared with 29.4% of HR-HPV positive women (p =
0.059). Interestingly, women with normal colposcopy
had the highest AI for E7, followed by those with high-
grade colposcopy (77.1%) and low-grade abnormality
(54.1%) (p = 0.011). AI was not related to HIV/smoking
status, being practically identical between the two groups
for both L and E antigens.
Correlation of HIV status to serological response
When the HIV status was taken into account (Table 2),
HIV-positive women showed less seroreactivity to E+L or
E and L separately than the HIV-negative ones. Interest-
ingly only the difference of seroreactivity to L antigens
reached statistical significance (Fisher's exact test; p =
0.030).
HIV-positive and current smoker women, showed the
lowest L seroprevalence (33.3%), as compared with
75.9% among all other women (p = 0.014; Fisher's exact
test), with OR = 0.158 (95%CI 0.036–0.695). This associ-
ation was not confounded by age, when tested either
using Mantel-Haenszel test for age groups (common OR =
0.178; 95%CI 0.038–0.832) (p = 0.028) or logistic regres-
sion analysis for age as continuous variable (adjusted OR
= 0.167; 95%CI 0.037–0.736) (p = 0.020). On the other
way round, women who are HIV-negative and not smok-
ers are significantly more likely to mount antibody
response (OR = 6.31; 95%CI 1.43–27.71).
Discussion
In a previous study we have reported the baseline data of
a cohort comprising HIV-positive and HIV-negative
women [39]. The present report provides data on HPV
exposure status of a group of these women that gave their
blood. The analysis regards the serological response to
recombinant HPV16 L1, L2, E4, E6 and E7 proteins eval-
uated by a new ELISA technique [34].
We have correlated the women's epidemiological charac-
teristics to their serological response to HPV16 antigens,
using three possible outcomes; i) seroreactivity to either E
or L (= HPV seropositive or not), ii) reactivity to E, and iii)
reactivity to L proteins. Only a few of the recorded epide-
miological variables proved to be significantly related to
serostatus of the women in this cohort. Interestingly cur-
rent smokers showed significantly less seroreactivity to L
antigens as compared with the non-smokers (OR = 3.7;
95%CI 1.3–10.5) (p = 0.009), while the difference in reac-
tivity to E and E+L antigens was not significant. This is in
full agreement with a recent report, where almost identi-
cal observations were reported [28]. In this study, smokers
were twice as likely as non-smokers to test negative for
anti-HPV L1 antibodies, even when the effects of other
covariates were considered in the analysis (adjusted OR =Infectious Agents and Cancer 2008, 3:9 http://www.infectagentscancer.com/content/3/1/9
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0.5; 95%CI 0.2–0.9). The relationship between tobacco
smoking and CC is highly complex; however, the basic
mechanisms must involve the host's inability to clear HR-
HPV infection. The observed failure of smokers to mount
antibody response to L antigens could be an indication of
the deregulation of immune responses induced by smok-
ing, increasing the likelihood of persistent infection and
the long-term risk for CC. This is in agreement with other
Table 2: Key clinical characteristics of the patients related to their serological response to HPV16 antigens
Variables Anti-E and -L Anti-E4-E6 and E7 Anti L1 and -L2
+ - Sign. + - Sign. + - Sign.
HPV DNA (%):
Positive 76 89.5 10.5 OR = 2.8 (0.8–9.9)  71.1 28.9 OR = 1.3 (0.4–3.7)  71.1 28.9 OR = 1.6 (0.6–4.6) 
p = 0.136 p = 0.604 p = 0.350
Negative 20 75.0 25.0 65.0 35.0 60.0 40.0
HR-HPV (%)
Positive 66 87.9 12.1 OR = 1.4 (0.4–4.8)  68.2 31.8 OR = 0.8 (0.3–2.0)  69.7 30.3 OR = 1.1 (0.5–2.9) 
p = 0.536 p = 0.608 p = 0.767
Negative 30 83.3 16.7 73.3 26.7 66.7 33.3
LR-HPV (%):
Positive 10 100 0.0 OR = NC  90.0 10.0 OR = 4.3 (0.5–30.0) 80.0 20.0 OR = 1.9 (0.4–9.7): 
p = 0.348 p = 0.273 p = 0.720
Negative 86 84.9 15.1 67.4 32.6 67.4 32.6
Previous:
HPV (%):
Yes 19 94.7 5.3 OR = 2.8 (0.3–23.9);  89.5 10.5 OR = 4.8 (1.1–22.8)  73.7 26.3 OR = 0.9 (0.3–3.1); 
p = 0.445 p = 0.046 p = 0.961
No 66 86.4 13.6 63.6 36.4 74.2 25.8
HIV-Status (%):
Negative 84 89.3 10.7 OR = 4.2(1.1–16.5)  71.4 28.6 OR = 1.8 (0.5–6.2)  72.6 27.4 OR = 3.7 (1.1–12.9) 
p = 0.032 p = 0.355 p = 0.030
Positive 12 66.7 33.3 58.3 41.7 41.7 58.3
Smokers 9 66.6 33.3 55.6 44.4 33.3 66.7
Previous:
PAP (%):
Never 10 90.0 10.0 p = 0.793 70.0 30.0 p = 0.111 80.0 20.0 p = 0.445
Irregular 26 92.3 7.7 84.6 15.4 61.5 38.5
Regular (1–3 yrs) 49 85.7 14.3 61.2 38.8 75.5 24.5
Referral
PAP (%):
ASC-US 7 100 0.0 p = 0.431 85.7 14.3 p = 0.623 100 0.0 p = 0.094
LSIL 48 91.7 8.3 64.6 35.4 75.0 25.0 p = 0.031*
HSIL 16 81.3 18.7 68.8 31.2 56.3 43.7
Biopsy
Result (%):
Normal 1 100 0.0 0.0 100 100 0.0
HPV-NCIN 9 100 0.0 p = 0.262 66.7 33.3 p = 0.526 77.8 22.2 p = 0.564
CIN1 11 90.9 9.1 54.5 45.5 63.6 36.4
CIN2 14 92.9 7.1 71.4 28.6 85.7 14.3
CIN3 15 93.3 6.7 73.3 16.7 73.3 26.7
SCC 2 50.0 50.0 50.0 50.0 50.0 50.0
Genital
Warts (%):
Yes 20 95.0 5.0 OR = 3.3(0.4–27.7)  80.0 20.0 OR = 2.1 (0.6–7.0)  75.0 25.0 OR = 1.1 (0.4–3.7) 
p = 0.437 p = 0.275 p = 0.801
No 61 85.2 14.8 65.6 34.4 72.1 27.9
Colposcopy (%):
Normal 2 100 0.0 100 0.0 0.0 100
Low-grade 27 96.3 3.74 p = 0.177 63.0 37.0 p = 0.668 85.2 14.8 p = 0.015
High-grade 28 77.8 22.2 72.2 27.8 61.1 28.9
NC, non-computable; 1Contraception used until past; 2Contraception in current use; *For linear trend; HPV-NCIN, HPV infection without CIN....Infectious Agents and Cancer 2008, 3:9 http://www.infectagentscancer.com/content/3/1/9
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results showing current smoking to be associated with
persistent HR-HPV infection [43,44].
The relationship of contraception and HPV infection has
been incompletely studied and only in relation with HPV
DNA detection [27,45,46], but not in relation to antibody
detection. In the present analysis only the condom use,
among the recorded epidemiological variables, was
related to seroreactivity to L antigens; the lowest (61.1%)
seropositivity (Table 1) was observed in those women
who reported to always use condom in sexual intercourse.
The relationship between HPV DNA detection and anti-
body response to different HPV antigens is highly com-
plex. Large sero-epidemiological studies seem indicate
that antibody response to viral antigens does not invaria-
bly occur during natural HPV infection [14,15]. Similarly,
only approximately half of HPV DNA-positive women
with normal cytology show antibody response to VLPs
[18,19]. Moreover E6/E7 antibodies are detected in
patients with CC as well as in healthy controls. [14,15,47].
These observations are confirmed in the present cohort,
where detection of HPV DNA, both LR+HR genotypes and
LR- and HR-HPV separately, did not bear any significant
relationship with seroreactivity to any viral antigens.
However women who reported past HPV infection show
a significantly higher prevalence (89.5%) of E antibodies
as compared with that (63.6%) of women who did not
reported past infection (OR = 4.8; 95%CI 1.1–22.8)
(Table 2). These results suggest that seropositivity to E
antigens could be considered as a surrogate for past viral
infection [48].
Into the HPV-PathogenISS cohort, HIV-positive women
were also enrolled [39]. As generally accepted, these
women are at increased risk for progression to CIN3 and
CC [49], mainly because of their failure to eradicate per-
sistent HR-HPV infection, even if treated by HAART [50].
HPV serology in HIV-positive women has been studied
only recently. In these women we have observed a signifi-
cantly lower seroprevalance compared to the HIV-nega-
tive ones; these data are in contrast with those reported in
large cohort studies, where HIV-positive women usually
have higher prevalence of HPV antibodies [51,25,29].
Some reasons of this discrepancy can be the small number
of HIV-positive women in our cohort leaving room for
observations by chance and the fact that all patients had
been on HAART for several years and their HPV baseline
status was very similar to that of HIV-negative women. On
the other hand, this observation could indicate their lower
HPV exposure in the past. A feasible explanation could be
the HIV-induced immunosuppression leading to per-
turbed early immune responses against HPV [50]; unfor-
tunately, the CD4 data of these women are incomplete
and it is not possible to draw firm conclusions on their
level of immunosuppression. With regard to the above
discussed failure of smokers to mount viral antibody
response, we analysed the combined effect of current
smoking and HIV-status in this cohort. Based on the
obtained results and our previously reported data [50,44],
it is tempting to speculate that HIV-positive women who
are current smokers comprise a special high-risk group,
with extremely high probability of developing CIN3/CC,
due to their failure to eradicate persistent HR-HPV infec-
tion. This failure could be attributed to their inability to
mount effective immunological responses against HPV
antigens, of which deregulation the low seroreactivity is
an indication.
Two other observations merit some discussion. We
noticed that seroresponse to L proteins declined in paral-
lel with the increasing severity of abnormality in the refer-
ral PAP smear, from 100% among ASCUS cases to 56.3%
among those with HSIL (Table 2)(p = 0.031 for linear
trend). This could substantiate the observations of Wiley
and collabotators [28] who reported that women with
ASCUS were twice more likely to test anti-HPV L1-positive
as compared with those with normal PAP. In our cohort,
we had no PAP-negative women to confirm this.
As recently discussed [34], most of the HPV antibodies
bound to these 5 antigens with an AI higher than 40%,
even in the sera from women infected with HPV type dif-
ferent from 16 type. When related to epidemiological data
and clinical observations, AI data yielded few significant
observations. No feasible explanation can be offered for
the association of high AI of anti-E7 antibodies in 100%
of women which did not use contraception in the past, as
compared with the 80% of those using contraception (p =
0.044). Similarly, the significant difference (p = 0.011)
obtained in AI between the different colposcopy catego-
ries does not show any linear trend with the grade of
abnormality.
Conclusion
In summary the results show that there is no meaningful
relationship between HPV DNA detection and seroreactiv-
ity to tested HPV antigens, which was not unexpected in
the light of published data [14,15,19]. However, two sig-
nificant observations are of particular interest. Current
smokers show significantly (p = 0.009) less seroreactivity
to HPV L antigens as compared with the non-smokers.
The difficulty of smokers to mount antibody response to
L antigens could be an indication of a marked deregula-
tion of the immune system responses thus increasing the
long-term risk for CIN3/CC. Another interesting observa-
tion is the significantly impaired seroreactivity to HPV L
antigens among HIV positive women, further accentuated
among women HIV positive and current smokers. It is
tempting to speculate that HIV positive women who areInfectious Agents and Cancer 2008, 3:9 http://www.infectagentscancer.com/content/3/1/9
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current smokers comprise a special high-risk group, with
extremely high probability of developing CIN3/CC, due
to their failure to eradicate persistent HR-HPV infection.
Methods
Patients
In the HPV-PathogenISS study a cohort of 286 women
were enrolled during 2002–2003 by Gynaecologic outpa-
tient departments at 5 hospitals (S. Orsola Malpighi,
Bologna; Istituto Regina Elena, Roma; Università di Tor
Vergata, Roma; Luigi Sacco, Milano; and Istituto San Gal-
licano, Roma). Women were selected for having abnor-
mal PAP test (ASC-US, LSIL or HSIL) [39]. The sera
examined in this study are from a group of 96 women of
this cohort that gave the informed consent for serum tak-
ing for research use. All women were subjected to colpos-
copy, PAP test (if not taken within the past 3 months),
biopsy (when indicated), as well as sampling for HPV
DNA testing. This study protocol was separately approved
by the institutional Ethical Committees of all 5 hospitals.
Epidemiological interview, Pap test, colposcopy, biopsy,
treatment by LLETZ are been previously described [39].
Sampling for HPV testing and HPV genotype identification
A careful sampling protocol for HPV testing was followed
in all clinics. Both exo- and endocervical specimens were
collected and stored at -70°C, until transported to the two
virology laboratories (Tor Vergata and ISS) for HPV anal-
ysis. HPV genotyping was performed by sequence analy-
sis, as previously described [34]. When the genotype was
not resolved by sequencing the samples were examined
for the presence of either HR- or LR- HPV by HC2 assay
(Digene). Because the genotype determination was not
possible for all samples the analysis reported in this paper
have been done by considering only the HR- and LR-HPV
categories.
HIV testing
The patient HIV-serostatus was determined at the entry
with ELISA test and confirmed by Western blot, with the
informed consent of the patients. The state of HIV disease
in sero-positive patients was assessed by CD4+ and CD8+
lymphocytes counting and recording the opportunistic
infections or neoplasia. Unfortunately CD4 parameter
was not available for all HIV-positive patients. All these
patients were being treated with highly active anti-retrovi-
ral treatment (HAART). HIV-positive patients in this study
were only 12, of whom 9 current smokers.
HPV serology
Human sera and control sera
The collection and treatment of sera of the 96 women
have been previously described [34]. Control sera were
randomly taken among sera collected for studies unre-
lated with HPV infection. As positive controls, antigen
specific hyper-immune sera obtained by injection in
either mice or rabbits of the recombinant purified HPV16
L1, L2, E4, E6 and E7 proteins were used [34].
ELISA and avidity test
The presence in the sera of anti-HPV antibodies was eval-
uated by an ELISA test based on the recombinant L1, L2,
E4, E6 and E7 HPV16 proteins [34]. A cut-off value for
each antigen was calculated as the arithmetic mean of the
absorbance values of 40 control sera, plus two standard
deviations (SD). After a first calculation the outlier values
were excluded and the cut-off recalculated [52]. The repro-
ducibility of ELISA results was assayed by testing each
serum in duplicate and repeating each test three times.
Avidity of the specific anti-HPV IgGs was evaluated and
the AI, expressed as a percentage of the absorbance in
ELISA with urea wash and the absorbance in ELISA with-
out urea wash × 100 [35]. Because of the lack of data
regarding the avidity antibodies in HPV infection, it was
difficult to establish an AI value discriminating between
low and high avidity. We tentatively assumed the 40%
value, a discriminating value reported for some infectious
diseases [40-42].
Statistical analyses
Statistical analyses were performed using the SPSS® soft-
ware package (SPSS for Windows, version 14.01). Fre-
quency tables were analysed using the Chi-square test,
with likelihood ratio (LR) or Fisher's exact test being used
to assess the correlation between categorical variables. OR
and 95% confidence intervals (95%CI) were calculated
where appropriate, using the exact method. Differences in
the means of continuous variables were analysed using
non-parametric tests (Mann-Whitney or Kruskal-Wallis)
or ANOVA (to obtain the mean values). Logistic regres-
sion analysis was used to control for the confounding
from age to some observed significant univariate predic-
tors of seroreactivity, e.g. HIV/smoking status. Confound-
ing was also controlled by calculating the common odds
ratio (OR) for the stratum-specific estimates, using the
Mantel-Haenszel test. To evaluate the statistical power of
the study (e.g. for age differences), we used STATA/SE 9.2.
power analysis option, with the default value (0.05) for
alpha, and using the true sample sizes of the women in the
two groups, e.g. seropositive and -negative women. In all
tests, the values p < 0.05 were regarded statistically signif-
icant.
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